-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OSW1VFdz9oRQ6JA3bSNWsBWq4FMWSie+cwGyCPJOwdlF3rqVu1G4yujH+sA6Tloi
 vAViymOfpu9+ok6nIdKZlA==

<SEC-DOCUMENT>0000732485-08-000021.txt : 20080804
<SEC-HEADER>0000732485-08-000021.hdr.sgml : 20080804
<ACCEPTANCE-DATETIME>20080804115712
ACCESSION NUMBER:		0000732485-08-000021
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20080715
FILED AS OF DATE:		20080804
DATE AS OF CHANGE:		20080804

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENZYME CORP
		CENTRAL INDEX KEY:			0000732485
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				061047163
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQ
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6172527500

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Bamforth Mark R
		CENTRAL INDEX KEY:			0001435745

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14680
		FILM NUMBER:		08987107

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		617-768-6010

	MAIL ADDRESS:	
		STREET 1:		500 KENDALL ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>bam395.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2008-07-15</periodOfReport>

    <dateOfOriginalSubmission>2008-07-17</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000732485</issuerCik>
        <issuerName>GENZYME CORP</issuerName>
        <issuerTradingSymbol>GENZ</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001435745</rptOwnerCik>
            <rptOwnerName>Bamforth Mark R</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>GENZYME CORPORATION</rptOwnerStreet1>
            <rptOwnerStreet2>500 KENDALL STREET</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Sr.VP, Corp. Operations &amp; Phar</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Genzyme NQ stock option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>32.52</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2008-07-15</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>6445</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>32.52</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2002-05-30</value>
            </exerciseDate>
            <expirationDate>
                <value>2012-05-30</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Genzyme common stock (GENZ)</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>6445</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>6445</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On July 17, 2008 reporting person filed a Form 4 for the exercise of an option and sale of shares under a 10b5-1 plan that did not meet the requirements of the plan, and the transaction was reversed.  The exercise of the option was originally reported as an acquisition.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>By: Susan P. Cogswell, Attorney-in-Fact</signatureName>
        <signatureDate>2008-07-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----